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Summary: Tissue factor pathway inhibitor, a natural anticoagulant in the extrinsic pathway of blood coagulation,
is associated with the endothelial membrane and presumed to be released by heparin.
For flow cytometric detection of membrane-bound tissue factor pathway inhibitor we synthesized polyclonal
monospecific antibodies directed against each of the three Kunitz-type domains. Antisera were obtained by
immunisation of rabbits with synthetic oligopeptides representing the reactive site of each domain. Kunitz-
domain 51: 26CAFKDDGPCKAIMKR41, domain 52: 101EDPGICRGYITR112 and domain 53: 192PADRGLCRA-
NENR204.
Different cell lines (chondrosarcoma, synovial sarcoma, synovial cells, leukaemic monocytes) and endothelial cells
were investigated by flow cytometric analysis using these antibodies. The three tissue factor pathway inhibitor
domains were detected on the surface of all cells by the corresponding antisera. Similar results were obtained by
immuno-histochemical staining. Since domain 53 was recognised by the appropriate antibody, it would seem that
this third domain is not the membrane binding site. To investigate the cellular tissue factor pathway inhibitor
release, endothelial cells were cultivated with heparin. Protein resynthesis and translocation were inhibited by
puromycin and monensin, respectively. After heparin incubation an increased tissue factor pathway inhibitor concen-
tration was determined in the cell culture medium by a chromogenic substrate assay. However, the tissue factor
pathway inhibitor density on the cell surface was not influenced by heparin, as shown by flow cytometry using the
three tissue factor pathway inhibitor antisera. Our results suggest that functionally active tissue factor pathway
inhibitor is not released from the cell surface. Therefore, the effect of heparin appears to be mediated by secretion
of tissue factor pathway inhibitor from intracellular stores.
Introduction plasma, in platelets and on the endothelial cell surface.
Tissue factor pathway inhibitor has been detected in hu- ^ Pathway of tissue factor Pathway id^tiuot 5^*-
man plasma, where it is associated with, and regulated sis'its Presentation on the cellular surface and its associ-
by, low density lipoprotein. It functions as a potent natu- ation with '^Proteins remains unclear (9). It has been
ral anticoagulant that regulates tissue factor-mediated sugSested that domain 3 is involved in the binding to
coagulation inhibition in the extrinsic pathway (1 -3). me cdl membrane> Hpoproteins, or in tissue factor path-
The native inhibitor consists of three Ointe-type inhibi- wa? inhibitor-degradation via low density lipoprotein re-
tor domains (1), connective chains and a negatively ceptor-related protein on hepatocytes (10).
charged N-terminus, the total relative molecular mass Injection of heparin has been found to result in a rapid
being approximately Mr 36000 to Mr 42000. The tissue dose-dependent 2—10 fold increase of tissue factor path-
factor pathway inhibitor gene has been localized on way inhibitor concentration in plasma (11, 12). The en-
chromosome 2 and the primary structure contains 276 dothelium bound tissue factor pathway inhibitor be-
amino acids including an acidic N-terminus, the three comes evident after injection of heparin in amounts
Kunitz-type inhibitory domains and a basic carboxy ter- equivalent to 50-90% of the total intravascular pool
minal end (4,5). Kunitz-domsiM 51 has been identified (13). Moreover, heparin effects the release of tissue
as the site of binding factor Vila/tissue factor complex, factor pathway inhibitor into endothelial cell culture su-
while domain 52 binds activated factor X (FXa). Tissue pernatant when added to the medium (14). The increased
factor pathway inhibitor is mainly synthesized by vascu- tissue factor pathway inhibitor activity suggested that
lar endothelium, where it is bound to heparan sulphate this inhibitor is involved in the post-heparin anticoagu-
or glycosaminoglycans (6,7), and by other cells, e. g. lant effect following heparin administration. A heparin
megakaryocytes and chondrocytes (8). There are three binding site C-terminal from domain 53 has been pos-
intravascular pools of tissue factor pathway inhibitor, in tulated as a mediator of heparin-induced tissue factor
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pathway inhibitor release from the cell surface (15).
However, it is also presumed that tissue factor pathway
inhibitor is released from intracellular stores (16). So
far, no results have been reported that show the protein-
turnover of membrane bound tissue factor pathway in-
hibitor.
We have already determined the influence of cyclo-
sporine on the vascular endothelium in heart transplant
patients, resulting in an increased tissue factor pathway
inhibitor plasma concentration (17, 18). These results
were described as cytotoxic or modulatory effects on the
endothelial cells (19).
In the present study we describe the flow cytometric
detection of tissue factor pathway inhibitor on endothe-
lial cells using three monospecific tissue factor pathway
inhibitor-antisera which recognize the reactive site of
Kunitz-type domain 51 and 52 as well as the correspond-
ing region of domain 53. We investigated the influence
of heparin on the release of membrane-bound tissue
factor pathway inhibitor from endothelial cells by flow
cytometry, and we suggest a potential mechanism for
tissue factor pathway inhibitor release from the vascular
endothelium.
Materials and Methods
All chemicals were purchased from the Sigma (Deisenhofen, Ger-
many) unless otherwise stated.
Synthesis of polyclonal rabbit antisera
The synthesis of the oligopeptides 26CAFKDDGPCKAIMKR41,
101EDPGICRGYITR112 and 192PADRGLCRANENR204 and the
immunisation of rabbits were performed using standard techniques
by QCB Inc. (Hopkinton, MA). For further use the antisera were
heated for 30 min at 56 °C and the IgG fraction was separated by
(NH4)2SO4 fractionation at 35% saturation followed by Protein A
affinity chromatography to remove residual proteins. The IgG was
then dialysed against HaO. Aliquots were then stored at -20 °C
until further use. As negative control non-immune rabbit IgG was
prepared from preimmunserum by (NILOaSCU precipitation fol-
lowed by dialysis as described above. Protein A absorption was
omitted.
Determination of cross-reactivities
All antisera were tested against each oligopeptide for specificity
and to exclude cross-reactivity. The antigens were immobilized
on an Immobilon AV® membrane (Millipore, Eschborn, Ger-
many) and incubated with each antiserum after 20 min blocking
with 20 g/1 casein. The detection was performed by standard
methods using anti-rabbit horse radish peroxidase1) monoclonal
antibodies.
Identification of tissue factor pathway inhibitor-
specific mRNA by reverse transcription PCR
For reverse transcription PCR the total mRNA2) was isolated from
different cell lines [endothelial cells (ECV304, EA.hy 926), chon-
drosarcoma (SW1353), synovial sarcoma (SW982), synovial cells
(McCoy) and leukaemic monocytes (THP-1)] according to the pro-
tocol from InstapureRNA-Kit (Eurogentec, Seraing, Belgium). Re-
verse transcription was performed with 1 μg RNA and 7pmol
oligo d(T)i5 primer by incubation at 40 °C for 90 min with 10 umol
dNTP and 200 U reverse transcriptase. The synthesized cDNA/
RNA hybrids were immediately used for the PCR2).
The following tissue factor pathway inhibitor specific primers were
used, resulting in the entire sequence of tissue factor pathway in-
hibitor domain 53 with 230 base pairs:
primer I: 3'-TTCCCAGCCTTTTTGAATTTCA-5'
primer II: 3'-TTAATCCGGAGGAAAACTATAAGAA-5'
The pCRII®-Kit (Invitrogen, De Shelp, The Netherlands) was used
for cloning and sequencing the PCR fragment of each cell line.
The PCR amplificates were confirmed by double stranded sequenc-
ing using the direct blotting technique (SERVA, Heidelberg, Ger-
many)
Cell culture
Human umbilical vein endothelial cells (Promocell, Heidelberg,
Germany) were incubated in serum-free growth medium contain-
ing human epidermal growth factor (10 μg/l), bovine brain ex-
tract (12 mg/1), hydrocortisone (1 mg/1) and antibiotics (50 mg/1).
EA.hy 926 endothelial cell line was kindly provided by Cora-
Jean S. Edgell (Department of Pathology, University of North
Carolina, NC, USA) and cultivated in RPM 1640, 100 g/1 foetal
calf serum with 5 mmol/1 hypoxanthine, 20 umol/1 aminopterin,
0.8mmol/l thymidine. All other cell lines (chondrosarcoma
SW1353, synovial sarcoma SW982, synovial cells (McCoy), leu-
kaemic monocytes THP-1, endothelial cell line ECV304) were
obtained from the American Type Culture Collection (Rockville,
MA, USA) and cultivated in M199 medium with 100 g/1 foetal
calf serum.
Flow cytometry
For flow cytometric analysis the cells were grown until 80%
confluence, then removed in 0.5 g/1 trypsin and 0.2 g/1 ethylene-
diaminetetraacetic acid. The cells were washed twice in Dul-
becco's phosphate-buffered saline containing 10 g/1 foetal calf
serum and resuspended at 106 cells per 100 μΐ. Each polyclonal
IgG fraction was added in a final dilution of 1:100 from the
stock solution. After Ih incubation at room temperature and
additional washing, the secondary polyclonal goat anti-rabbit flu-
orescein labelled antibody F(ab')2-fragment (Dianova, Hamburg,
Germany) was added in a final dilution of 1:200. After Ih
incubation at room temperature the cells were washed twice in
Dulbecco's phosphate-buffered saline containing 10 g/1 foetal calf
serum and resuspended in 500 μΐ Dulbecco's phosphate-buffered
saline containing 10 g/1 foetal calf serum for flow cytometric
analysis in a fluorescence activated cell sorting analyser using
CELLQuest® software (Becton Dickinson, Heidelberg, Ger-
many). Negative controls were performed with either no primary
antibody or preimmune IgG fraction. For positive control a
mouse anti-HLA-ABC monoclonal antibody (DAKO Diagnos-
tica, Hamburg, Germany) was used.
Immunohistochemistry
The cells were washed three times in phosphate-buffered saline
at 4 °C to remove traces of culture medium, then resuspended in
phosphate-buffered saline at an approximate cell concentration of
2xl09/l. The suspension (50—ΙΟΟμΙ) was pipetted onto a pre-
marked area of silanized glass slides and allowed to settle for 10
!) Enzymes:
Factor VII (EC 3.4.21.2)
Factor X (EC 3.4.21.6)
Peroxidase from horseradish (EC 1.11.1.7)
2) Abbreviations
cDNA, copy deoxyribonucleic acid
DNA, deoxyribonucleic acid
dNTP, 2'-deoxynucleoside 5'-triphosphate
PCR, polymerase chain reaction
RNA, ribonucleic acid
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min. Residual suspension was removed by tapping and the cells
were air dried for a further 10 min. The slides were then fixed in
30 g/1 paraformaldehyde in phosphate-buffered saline for l h and
washed in distilled water. The slides were passed through graded
aqueous solutions of absolute ethanol then air dried at 4 °C. Prior
to staining the preparations were rehydrated in phosphate buf-
fered saline.
Tissue factor pathway inhibitor activity assay
The inhibitory activity of tissue factor pathway inhibitor in cell
culture supernatant was measured by a modified chromogenic
substrate assay based on the ability to inhibit factor X1} activa-
tion by factor Vila/tissue factor1) complex. Tissue factor (25 μΐ,
dilution 1:80, Baxter, Unterschlei heim, Germany) and 25 μΐ
factor VII (0.0125 U) were added to 25 μΐ 0.075 mol/1 CaCl2
and 25 μΐ factor X (0.025 U) and incubated for 15 min at 37 °C
with vigorously shaking. Heat-inactivated sample (25 μΐ, dilution
up to 1:20) was added, followed by incubation again for 15 min
at 37 °C with vigorous shaking. A further 25 μΐ factor X (0.4 U)
were then added immediately, and the incubation continued for
10 min at 37 °C. The chromogenic reaction was then started by
adding 25 μΐ synthetic substrate (2.7 mol/1 N-benzoyl-Ile-Glu-
Gly-Arg-p-nitroanilide, Chromogenix, Essen, Germany). The ab-
sorbance was measured at 405 run after 30 min. The clotting
factors and samples were diluted in assay buffer containing
0.05 mol/1 Tris/HCl, 0.1 mol/1 NaCl and 10 g/1 human albumin
(Armour Pharma, Eschwege, Germany), pH 8.O. For quantifica-
tion the test sytem was calibrated with truncated recombinant
tissue factor pathway inhibitor (19).
Results
Determination of antisera specificity
The antisera were used in a dot blot assay against each
synthesized oligopeptide. Staining with a secondary
anti-rabbit horse radish peroxidase monoclonal antibody
was only observed with the corresponding antigen.
Thus, we found no cross-reactivity with either of the
other domain-specific recognition sites (tab. 1). Further-
more, free plasma tissue factor pathway inhibitor was
detected in a dot blot assay by all antisera (data not
shown). This indicates the specificity of the immunglo-
bulin fractions toward the complete tissue factor path-
way inhibitor protein and demonstrates the presence of
all tissue factor pathway inhibitor domains in the
plasma.
Flow cytometric tissue factor pathway
inhibitor detection with polyclonal IgG
fractions
The purified IgG fractions of each antiserum were used
to detect tissue factor pathway inhibitor on the cell sur-
face. The titre was 1:100 with IgG stock solution pre-
pared from 10 ml rabbit serum. All tissue factor pathway
inhibitor single domains were detected by the corre-
sponding antiserum on the surface of endothelial cells
(human umbilical vein endothelial cells) and endothelial
cell lines (EA.hy 926, ECV304) by flow cytometry (fig.
1). Since tissue factor pathway inhibitor was not de-
tected in the supernatant after trypsin/ethylenediamine-
tetraacetic acid treatment (data not shown) it is con-
cluded that this treatment did not release the membrane-
bound inhibitor. The fluorescence intensity in the flu-
orescein isothiocyanate channel (FL1) was approxi-
mately 50% (102 events) compared with the density of
HLA-ABC antigens (103 events). The overall tissue
factor pathway inhibitor expression on endothelial cells
and two endothelial cell lines was significantly higher
than that on other cell lines such as synovial cells
(McCoy), synovial sarcoma (SW982), chondrosarcoma
cells (SW982) and leukaemic monocytes (THP-1) (fig.
2). This is in accordance with the observation that endo-
thelial cells are the main source of the inhibitor.
Immunostaining of fixed endothelial cells
with the monospecific antisera
In immunohistochemical experiments we were also able
to stain fixed endothelial cells with each of the three
300 300
10° 101 102 103 104
Fluorescence
10° 101 102 1Q3
Fluorescence
Tab. 1 Schematic presentation of the specificity of antisera
against each oligopeptide. The peptides Ρδΐ, Ρδ2 and Ρδ3 were
recognized only by the corresponding antisera against the reactive
site of the Kunitz-type single domain. Phosphate-buffered saline
was used as negative control.
Peptides
Ρδΐ
P52
Ρδ3
Plasma
Serum
Antisera against tissue factor
pathway inhibitor
Phosphate-
buffered
saline
51 52 53
300
10° 101 102 1Q3 1Q4
Fluorescence
300
10" 101 102 1Q3
Fluorescence
Fig. 1 Flow cytometric analysis of endothelial cells using tissue
factor pathway inhibitor single domain specific IgG fractions, (a),
negative control with IgG fraction from preimmunserum; (b), anti-
domain 51 antibody; (c), anti-domain 52 antibody; (d), anti-domain
53 antibody. Fluorescence is given in arb. units.
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Fluorescence
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1QQ 10' 102 1Q3 1Q4
Fluorescence
10° 101 102 1Q3 104
Fluorescence
2561 300
λ
10° 101 1Q2 1Q3 104
Fluorescence
10° 101 102 1Q3 1Q4
Fluorescence
Fig. 2 Flow cytometric analysis of different cell lines using tissue
factor pathway inhibitor specific IgG fraction against the single
domain 51.
(a) Preimmunserum as negative control, (b) endothelial cell line
ECV304 [white] und EA.hy926 [gray], (c) chondrocytes, (d) mo-
nocytes, (e) chondrosarcoma, (f) synovial cells. Fluorescence is
given in arb. units.
tissue factor pathway inhibitor-specific IgG fractions.
The associated primary antibodies were detected with
a secondary anti-rabbit horse radish peroxidase-coupled
antibody. The optimal titres of IgG fractions were deter-
mined as 1:500.
Effect of heparin on the tissue factor pathway
inhibitor presentation on the cell surface
To evaluate the tissue factor pathway inhibitor releasing
effect of heparin, we analysed endothelial cells after
heparin incubation by flow cytometry with our three
polyclonal antibodies. To exclude fast tissue factor path-
way inhibitor resynthesis and presentation, either the
cellular protein synthesis or translocation were inhibited,
using monensin or puromycin, respectively. In compari-
son with endothelial cells incubated without heparin, the
tissue factor pathway inhibitor density on the surface of
cells incubated after addition of low-molecular-weight
heparin was only slightly decreased (fig. 3). Similar re-
sults were obtained in the presence and absence of
monensin or puromycin.
Measurement of tissue factor pathway
inhibitor concentration in the culture medium
The tissue factor pathway inhibitor concentration was
measured in the cell culture medium (105 cells per well)
of endothelial cells after addition of 10000 U/l heparin
and without heparin over a period of 48 hours by a chro-
mogenic substrate assay. Our results clearly demonstrate
a heparin-mediated tissue factor pathway inhibitor re-
lease from endothelial cells into the extracellular space
(fig. 4). Incubation with heparin (10000 U/l) results in a
2—4 fold increased tissue factor pathway inhibitor con-
centration (140—280 μg/l) compared with cells culti-
vated without heparin (80—130 μg/l).
Detection of tissue factor pathway
inhibitor-specific mRNA
In addition to endothelial cells and endothelial cell lines
ECV304/EA.hy 926, tissue factor pathway inhibitor-
specific DNA transcription products were also detected
in chondrosarcoma (SW1353), synovial sarcoma
(SW982), synovial cells (McCoy) and leukaemic mono-
cytes (THP-1) by reverse transcription PCR. The cloned
PCR-fragments were identified as the coding region of
256
256
100 101 102 1Q3
Fluorescence
104 10° 101 102 103 1Q4
Fluorescence
256 2561
10° 101 102 1Q3 1Q4
Fluorescence
10° 101 102 1Q3 104
Fluorescence
Fig. 3 Flow cytometric analysis of endothelial cells under the
influence of heparin. (a) Negative control with IgG fraction
from preimmunserum; (b) anti-£«mf -type domain 51 antibody,
(a) without heparin, (b) after addition of 10000 U/l low-molecu-
lar-weight heparin; (c) anti-domain 52 antibody, (a) without hep-
arin, (b) after incubation with 10000 U/l low-molecular-weight
heparin for 30 minutes; (d) anti-domain 53 antibody, (a) without
heparin, (b) after incubation of 10000 U/l low-molecular-weight
heparin for 30 minutes. Protein resynthesis was inhibited by
puromycin. Incubation with monensin gave similar results (data
not shown). Fluorescence is given in arb. units.
Tiemann et al.: Three Kunitz-type domains of tissue factor pathway inhibitor 859
*- 80
I
60
«
20
12
Time [h]
24 48
Fig. 4 Measurement of the tissue factor pathway inhibitor con-
centration in endothelial cell culture supernatant using a chromo-
genic substrate assay. The cells were incubated with (·-·) or with-
out (A-A) heparin (10000 U/l) over a period of two days. The
values represent the mean (per 105 cells).
tissue factor pathway inhibitor domain 63 by DNA se-
quencing (data not shown).
Discussion
Tissue factor pathway inhibitor, which is mainly synthe-
sized by endothelial cells, is a natural anticoagulant in
the extrinsic pathway of blood coagulation (20). The
main activity of tissue factor pathway inhibitor is to
downregulate the initial activation of coagulation result-
ing from exposure of tissue factor to the blood (21—22).
This activity is increased after in vivo administration of
low-molecular-mass heparin (23).
Heparin and fractionated low-molecular-mass heparin
(24) induce increased plasma levels of tissue factor
pathway inhibitor in vivo after subcutaneous admin-
istration and in endothelial cell culture supernatant
(12—14). The increased inhibitor concentration appears
to be mediated by the release of tissue factor pathway
inhibitor from the endothelial cell surface where tissue
factor pathway inhibitor is possibly present in associa-
tion with proteoglycans (25), or from intracellular
stores. Thus, tissue factor pathway inhibitor may func-
tion as an important regulator of thrombin formation
on the vascular surface.
Our interest was focused on tissue factor pathway
inhibitor presentation on the cell surface. Determina-
tion of the surface expression by flow cytometric
methods was made possible by our new monospecific
polyclonal antibodies (fig. 5). These antibodies were
obtained by immunization of rabbits with synthetic
oligopeptides representing the reactive site of each
Kunitz-type domain.
Each tissue factor pathway inhibitor single domain
was detected by the corresponding antiserum on the
surface of endothelial cells (human umbilical vein en-
dothelial cells, ECV304, EA.hy 926), synovial cells,
synovial sarcoma, chondrosarcoma and leukaemic mo-
nocytes. We also determined tissue factor pathway
inhibitor-specific mRNA-transcripts in these cell lines
to ensure that tissue factor pathway inhibitor gene
transcription had occurred.
As the main source of vascular tissue factor pathway
inhibitor, endothelial cells showed a higher surface ex-
pression of the inhibitor compared with other tested cell
lines. According to the results of flow cytometry, hepa-
rin did not release surface bound tissue factor pathway
inhibitor from endothelial cells. Even when protein syn-
thesis and translocation were inhibited by monensin or
puromycin, heparin did not alter significantly the tissue
factor pathway inhibitor density on the endothelial cell
surface. However, we found an increased tissue factor
pathway inhibitor concentration in the extracellular
space with our chromogenic substrate assay. This sug-
gests that membrane-bound tissue factor pathway inhibi-
tor is not the source of elevated inhibitor concentrations
after heparin induction. Increased tissue factor pathway
inhibitor levels, as measured in the cell culture superna-
tant after heparin incubation, might be derived from in-
tracellular stores, as shown for von Willebrand factor,
which is derived from Weibel-Palade bodies or secreted
directly from the endothelial cytosol (26).
The third domain 53 of tissue factor pathway inhibitor
has been postulated as the binding site on the cell sur-
face, where it mediates, in combination with the C-termi-
nus, the association with other molecules, e. g. proteo-
glycans, lipoproteins and heparin (5, 27). The antibody
to domain 53 (Pro192—Arg204) bound to the cell surface
with no decrease of affinity. Thus, the association of
the inhibitor with cell membrane proteoglycans did not
involve this region of the tissue factor pathway inhibitor
protein. Furthermore, the recognition of domain 53 was
Fig. 5 Secondary structure of tissue factor pathway inhibitor. The
black amino acids demarcate both the reactive site of the Kunitz-
type domain and the corresponding synthetic oligopeptide se-
quence for immunization.
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not influenced by heparin. We therefore suggest that the
C-terminus, and not the third domain, is probably the
tissue factor pathway inhibitor binding site. The releas-
ing effect of heparin remains unclear even though strong
evidence points to an intracellular mechanism.
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